Arthneeti
HL

Haleos Labs Limited

Q2 FY27Pharmaceuticals & Biotechnology

Haleos Labs Q2 Results 2026: PAT ₹2 Cr, Revenue ₹91 Cr

Q2 FY27 results statement: what the company reported on revenue, margins and capex.

Revenue
₹91Cr
Net profit
₹2Cr
Margin
9.1%

Haleos Labs Limited Q2 FY27 key numbers

Revenue
Revenue from Operations for the quarter ended 30th September 2026: Rs. 8,820.38 Lakhs (Standalone, page 3).

As stated in Haleos Labs Limited's Q2 FY27 results statement · published 11 Nov 2026. Reported figures, not investment advice.

Based on Haleos Labs Limited's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.

Price₹1,399
Market cap₹407 Cr
P/E25.8

The short version

Revenue from Operations for the quarter ended 30th September 2026: Rs. 8,820.38 Lakhs (Standalone, page 3). The presentation on page 15 reports quarterly financials.

From Haleos Labs Limited's Q2 FY27 earnings-call transcript · updated 11 Nov 2026.

How did Haleos Labs' revenue grow in the September 2026 quarter?

  • Revenue from Operations for the quarter ended 30th September 2026: Rs. 8,820.38 Lakhs (Standalone, page 3).
  • Revenue for the corresponding quarter ended 30th September 2025: Rs. 7,784.35 Lakhs.
  • Year-on-year growth in revenue from operations: Rs. 8,820.38 Lakhs vs Rs. 7,784.35 Lakhs, an increase of Rs. 1,036.03 Lakhs (~13.3% growth).

What happened to Haleos Labs' margins in Q2 FY27?

See what Haleos Labs Limited said on profitability & margins — free account, 30 seconds.

What capex is Haleos Labs planning?

The presentation (pages 15 and related notes) mentions the following regarding capex, capacity expansion, or new projects: - Capital Work-in-Progress amounts to Rs. 3,003.35 lakhs as of Sept 30, 2026 (up from Rs. 1,042.21 lakhs in March 2026), indicating ongoing investments in new assets or capacity expansion. - Corporate Guarantee extended to Mahi Drugs (subsidiary) related to an ECR loan of Rs. 150 Crores (Page 15), implying funding related to expansion or operations. - The company’s business is manufacturing Active Pharmaceutical Ingredients and intermediates as a single reportable segment; investment likely aligns with this sector.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1Ind-Swift Laboratories
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Is Haleos Labs raising money or cutting debt?

See what Haleos Labs Limited said on fundraising & capital structure — free account, 30 seconds.

How big is Haleos Labs' order book?

See what Haleos Labs Limited said on order book & pipeline — free account, 30 seconds.

Haleos Labs Limited — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Haleos Labs Limited Q2 FY27 results — key figures

Haleos Labs Limited Q2 FY27 reported results vs year-ago quarter, ₹ crore
₹ CrQ2 FY27
Revenue91
Operating profit (EBITDA)8
Operating margin9.1%
Profit before tax2
Net profit (PAT)2
EPS (₹)10.77

Source: Haleos Labs Limited's results filing to NSE (consolidated), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹91 Cr, net profit ₹2 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

More Q2 FY27 results in Pharmaceuticals & Biotechnology

All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings

Continue your research

Others in Pharmaceuticals & Biotechnology this season

  • Bal Pharma (Q2 FY27)

    Revenue from operations (Consolidated) for Q2 FY 2026-27: ₹8,994.69 lakhs, up from ₹7,402.49 lakhs in Q2 FY 2025-26, reflecting a year-on-year increase of…

  • Bafna Pharmaceuticals (Q2 FY27)

    INR 3,546.82 Lakhs, approximately 34.4% increase. Key results statement takeaways from Bafna Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks

  • Quest Laboratories (Q2 FY27)

    Revenue from operations for the half year ended 30th September 2026 is ₹5,533.55 lakhs, compared to ₹4,880.48 lakhs for the half year ended 30th September…

  • Curis Lifesciences (Q2 FY27)

    2790.89 lakh for the quarter ended 30.09.2025 (standalone), indicating a year-on-year increase of approximately 32.8%. Key results statement takeaways from Curi

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Haleos Labs Limited and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Haleos Labs Limited Q2 FY27 results?

Revenue from Operations for the quarter ended 30th September 2026: Rs. 8,820.38 Lakhs (Standalone, page 3). The presentation on page 15 reports quarterly financials.

What is Haleos Labs Limited share price analysis?

Haleos Labs Limited currently shows a neutral. The stock trades at a P/E of 25.8 with a market cap of ₹407 Cr. Investors should review the full earnings analysis for detailed insights.

Is Haleos Labs Limited planning capital expenditure?

The presentation (pages 15 and related notes) mentions the following regarding capex, capacity expansion, or new projects:.

Keep Haleos Labs Limited on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.